WEST LAFAYETTE, Ind., Feb. 21, 2019 (GLOBE NEWSWIRE) — Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) is pleased to announce that Joe Flynn has been appointed as Chief Commercial Officer of the Company, effective as of February 21, 2019. Mr. Flynn will be responsible for leading sales and marketing efforts across BASi’s three sites located in West Lafayette and Evansville, Indiana, and St. Louis, Missouri.
Mr. Flynn has an esteemed career as a senior executive in contract research, with over 25 years of strategic and operational experience focusing on pharmaceutical research and development. Most recently, he served as Chief Commercial Officer and Executive Vice President of Seventh Wave Laboratories. Mr. Flynn joined BASi in July of last year when BASi acquired the operations of Seventh Wave in order to provide broader solutions and greater scientific expertise to its clients.
“I have great confidence in Joe and his ability to shape our commercial engine,” said Robert Leasure, Jr., BASi’s President and Chief Executive Officer. “The team Joe has in place is solidly positioned to help drive our internal growth objectives and support any external opportunities we have in the future. Joe will play a vital role on our leadership team and brings a valuable combination of laboratory experience, industry knowledge, and commercial leadership. His appointment fills one more critical position towards our Company’s growth and ability to support our clients.”
Prior to his tenure at Seventh Wave Laboratories, Mr. Flynn was a global vice president of sales and client services for multiple divisions of Covance Laboratories. Prior to Covance, he held operational roles at PPD Inc. and ABC Laboratories (now Eurofins). Mr. Flynn began his career with a BS in Biochemistry from the University of Missouri, Columbia.
“I am enthusiastic about the opportunities before us, and proud to be a part of this team. Our position—being small enough to be responsive but big enough to deliver—is already resonating with clients. We have good momentum and are building backlog and serving our loyal clients, while layering in new clients every day. With modest enhancements to our commercial engine, we have a great opportunity to differentiate our integrated offerings and help our clients exceed their goals.”
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world’s leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. BASi’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit www.BASinc.com for more information about BASi.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, and various market and operating risks detailed in the company’s filings with the U.S. Securities and Exchange Commission.
Jill C. Blumhoff
Chief Financial Officer